TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
NextCell Pharma AB
Closing information (x1000 DKK)
| Closing information | 2024/08 | 2023/08 | 2022/08 |
| Turnover |
7,018
|
6,364
|
3,892 |
| Financial expenses |
1
|
2
|
10 |
| Earnings before taxes |
-27,610
|
-25,053
|
-24,060 |
| EBITDA |
-27,766
|
-25,520
|
-24,069 |
| Total assets |
53,489
|
55,897
|
86,796 |
| Current assets |
39,892
|
42,333
|
74,333 |
| Current liabilities |
6,497
|
6,343
|
4,827 |
| Equity capital |
44,481
|
47,653
|
80,449 |
| - share capital |
9,860
|
4,435
|
4,907 |
| Employees (average) |
24
|
17
|
15 |
Financial ratios
| Fiscal year | 2024/08 | 2023/08 | 2022/08 |
| Solvency |
83.2%
|
85.3%
|
92.7% |
| Turnover per employee |
292
|
374
|
259 |
| Profit as a percentage of turnover |
-393.4%
|
-393.7%
|
-618.2% |
| Return on assets (ROA) |
-51.6%
|
-44.8%
|
-27.7% |
| Current ratio |
614.0%
|
667.4%
|
1539.9% |
| Return on equity (ROE) |
-62.1%
|
-52.6%
|
-29.9% |
| Change turnover |
363
|
2,847
|
1,168 |
| Change turnover % |
5%
|
81%
|
43% |
| Chg. No. of employees |
7
|
2
|
2 |
| Chg. No. of employees % |
41%
|
13%
|
15% |
Total value of public sale
| Fiscal year | 2024/08 | 2023/08 | 2022/08 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.